Novel muc1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hu, Yan ^a   Duan, Jinhong ^a   Zhan, Qimin ^b   Wang, Fengdan ^c   Lu, Xin ^c   Yang, Xian Da ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CANCER HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APTAMER; DOXORUBICIN; EPITOPE; MUCIN 1; AMINO ACID; ANTINEOPLASTIC AGENT; MUC1 PROTEIN, HUMAN; PEPTIDE APTAMER; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DNA STRUCTURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; LUNG CANCER; PROTEIN BINDING; ADENOCARCINOMA; CELL SURVIVAL; CHEMISTRY; DRUG DESIGN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; KINETICS; METABOLISM; METHODOLOGY; STATISTICAL MODEL; TUMOR CELL LINE;

ADENOCARCINOMA; AMINO ACIDS; ANTINEOPLASTIC AGENTS; APTAMERS, PEPTIDE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MODELS, STATISTICAL; MUCIN-1; PROTEIN BINDING; RNA, SMALL INTERFERING;

EID: 84863145260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031970     Document Type: Article

References (31)

1. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103: 6315-6320.
2. Adams GP, Weiner LM, (2005) Monoclonal antibody therapy of cancer. Nat Biotech 23: 1147-1157.
3. Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, et al. (2009) A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results. Journal of Clinical Oncology 27.
4. Ye X, Yang D, (2009) Recent advances in biological strategies for targeted drug delivery. Cardiovasc Hematol Disord Drug Targets 9: 206-221.
5. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M, (1999) MUC1 and cancer. BBA-Mol Basis Dis 1455: 301-313.
6. Vasir JK, Labhasetwar V, (2005) Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 4: 363-374.
7. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC, (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26: 442-449.
8. Brown KC, (2010) Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications. Curr Pharm Des 16: 1040-1054.
9. Sudimack J, Lee RJ, (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41: 147-162.
10. Osborne SE, Matsumura I, Ellington AD, (1997) Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol 1: 5-9.
11. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ, (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 105: 17356-17361.
12. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, et al. (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672.
13. Farokhzad OC, Karp JM, Langer R, (2006) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 3: 311-324.
14. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, et al. (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10: 862-868.
15. Ferreira CSM, Matthews CS, Missailidis S, (2006) DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers. Tumor Biol 27: 289-301.
16. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariepy J, (2009) Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 37: 866-876.
17. Davis KA, Abrams B, Lin Y, Jayasena SD, (1996) Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res 24: 702-706.
18. Ren J, Agata N, Chen D, Li Y, Yu WH, et al. (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175.
19. Gendler SJ, (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293.
20. Murray A, Spencer DI, Missailidis S, Denton G, Price MR, (1998) Design of ligands for the purification of anti-MUC1 antibodies by peptide epitope affinity chromatography. J Pept Res 52: 375-383.
21. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A, (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69: 1-11.
22. Ren L, Marquardt MA, Lech JJ, (1997) Estrogenic effects of nonylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7. Chem Biol Interact 104: 55-64.
23. Cao Y, Karsten U, Otto G, Bannasch P, (1999) Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and α2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Archiv 434: 503-509.
24. Croce M, Isla-Larrain M, Capafons A, Price M, Segal-Eiras A, (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women*. Breast Cancer Res Tr 69: 1-11.
25. Haj HT, Salerno M, Priebe W, Kozlowski H, Garnier-Suillerot A, (2003) New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem Biol Interact 145: 349-358.
26. Burchell JM, Mungul A, Taylor-Papadimitriou J, (2001) O-linked glycosylation in the mammary gland: Changes that occur during malignancy. Journal of Mammary Gland Biology and Neoplasia 6: 355-364.
27. Lee Y, Park SY, Mok H, Park TG, (2008) Synthesis, characterization, antitumor activity of pluronic mimicking copolymer micelles conjugated with doxorubicin via acid-cleavable linkage. Bioconjug Chem 19: 525-531.
28. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, et al. (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672.
29. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103: 6315-6320.
30. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, et al. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
31. Senter PD, Svensson HP, Schreiber GJ, Rodriguez JL, Vrudhula VM, (1995) Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers. Bioconjug Chem 6: 389-394.